MediPoint: Peripheral Vascular Stents for the Lower Extremity - US Analysis and Market Forecasts

Reportbuyer.com just published a new market research report: MediPoint: Peripheral Vascular Stents for the Lower Extremity - US Analysis and Market Forecasts.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

London (PRWEB) September 19, 2013

Summary

Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease (PAD) in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone. The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India. Through GlobalData’s analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.

The peripheral vascular stent market is a large and dynamic one that allows stent manufacturers to develop different types of vascular stent platforms for different types of arteries in the lower extremity. As PAD presents enormous global public health and socioeconomic issues, it is pertinent to find effective treatment modalities that ensure long-term quality results for patients. This report looks at the current peripheral vascular stent market for the lower extremity in the US, and evaluates the adoption and opportunities for this technology.

Scope

  • An overview of PAD, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized US PVS market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
  • Investigation of current and future market competition for PVS
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the PVS sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy:

  • Understand the trends shaping and driving the US PVS Market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the US PVS Market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What’s the next big thing in US PVS market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 7
1.1 List of Tables 14
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 25
2.2 Related Reports 25
3 Peripheral Artery Disease 26
3.1 Overview 26
3.2 Anatomy and Physiology 26
3.2.1 Peripheral Arteries of the Lower Extremity 27
3.3 Pathophysiology 28
3.4 Clinical Presentation 30
3.4.1 Symptoms of Peripheral Artery Disease 30
3.4.2 Risk Factors 32
3.4.3 Disease Classification 32
3.4.4 Diagnosis 33
3.5 Clinical Outcomes 34
3.5.1 Treatment Paradigm 34
3.5.2 Treatment Guidelines 35
3.5.3 Treatment Modalities 39
3.5.4 Endovascular Management of PAD 54
3.6 Epidemiology 57
3.6.1 Peripheral Artery Disease 57
3.7 Economic Impact 59
3.7.1 United States 60
3.8 Treatment Costs 61
4 Unmet Needs 63
4.1 Need for Better Clinical Outcomes in Specific Lesions 63
4.1.1 Chronic Total Occlusions 63
4.1.2 Long Lesions 63
4.1.3 Heavily-Calcified and Uncrossable Lesions 64
4.1.4 Bifurcation Lesions 64
4.2 Need to Improve Medical Therapy 64
4.3 Comparative Studies on Exercise Therapy 65
4.4 Addressing Complications of Lower-Extremity Bypass Surgery 65
4.5 Eliminating Mechanisms of Failure with Balloon Angioplasty 66
4.6 Need for Better Revascularization of the Femoropopliteal Artery 66
4.7 Difficulty in Treating the Infrapopliteal Artery 67
4.8 Lack of Clinical Data 68
4.9 Limited Designs of Low-Profile Devices 69
4.10 Addressing Challenges of Peripheral Stenting 69
4.10.1 Risk of Post-Procedural Complications 69
4.10.2 In-Stent Restenosis 71
4.10.3 Stent Fracture 71
4.10.4 Long-Term Vessel Patency 72
4.10.5 Stent Material 72
4.10.6 Stent Deployment and Deliverability 73
4.10.7 Dual Anti-Platelet Therapy 74
4.10.8 Imaging 74
5 Industry Overview 75
5.1 Procedure Trends 75
5.1.1 Factors Contributing to Rise of Peripheral Interventions 75
5.1.2 United States 75
5.2 Market Access 78
5.2.1 United States 78
5.3 Reimbursement Trends 82
5.3.1 United States 82
5.4 Regulatory Issues/Recalls 84
5.4.1 Regulatory Issues 84
5.4.2 Recalls 84
5.5 Mergers and Acquisitions 85
5.5.1 Abbott Laboratories 85
5.5.2 Atrium Medical Corporation 86
5.5.3 Boston Scientific Corporation 86
5.5.4 Cordis Corporation (Johnson & Johnson) 87
5.5.5 Covidien 87
5.5.6 CR Bard 87
5.5.7 Medtronic 88
5.5.8 Nexeon Stent 88
5.5.9 Terumo Corporation 89
6 Competitive Assessment 90
6.1 Overview 90
6.1.1 Peripheral Vascular Stent Market 90
6.2 Products 93
6.2.1 Bare Metal Stents 93
6.2.2 Drug-Eluting Stents 167
6.2.3 Covered Stents 173
6.2.4 Bioabsorbable Stents 183
7 Pipeline Products 186
7.1 Overview 186
7.2 Pipeline by Phase of Development 187
7.3 Pipeline Product Profiles – Peripheral Artery Disease 189
7.3.1 Citation Stent 189
7.3.2 MR-Enhanced Stents 190
7.3.3 ArtiStent 191
7.3.4 Hybrid Dynamic Stent 191
7.3.5 Nipro Corporation Peripheral Stent 191
7.3.6 Yukon 191
7.3.7 iCAST 193
7.3.8 Peritoneal-Lined Stents 194
7.3.9 LifeJacket Stent Graft 195
7.3.10 Esprit Bioabsorbable Vascular Scaffold (BVS) 196
7.3.11 Magic Explorer Stent 197
7.3.12 Stanza 198
7.3.13 3D Biotek Bioresorbable Stent 200
7.3.14 Archer Stent 201
7.3.15 ART Stent 202
7.3.16 Amaranth Bioabsorbable Scaffold 202
7.3.17 TephaFLEX Absorbable Peripheral Stent 202
7.3.18 Zorion Medical Stent 203
7.3.19 Summary 203
8 Clinical Trial Analysis 204
8.1 Overview 204
8.2 Trials to Watch 205
8.2.1 Abbott Vascular 205
8.2.2 Atrium Medical Corporation 206
8.2.3 Biotronik 207
8.2.4 480 Biomedical 207
8.2.5 Cook Medical 208
8.2.6 Covidien 209
8.2.7 Flexible Stenting Solutions 210
8.2.8 IDEV Technologies 210
8.2.9 Medtronic 211
8.2.10 Terumo Medical Corporation 213
9 Current and Future Players 214
9.1 Overview 214
9.2 Trends in Corporate Strategy 215
9.3 Company Profiles 217
9.3.1 Abbott Vascular 217
9.3.2 Amaranth Medical 220
9.3.3 Arterial Remodeling Technologies 222
9.3.4 Atrium Medical Corporation 224
9.3.5 Bard Peripheral Vascular (C.R. Bard) 226
9.3.6 Biotronik 228
9.3.7 Boston Scientific Corporation 230
9.3.8 3D Biotek 232
9.3.9 480 Biomedical 233
9.3.10 Cook Medical 235
9.3.11 Cordis Corporation (Johnson & Johnson) 237
9.3.12 CorInnova 239
9.3.13 Covidien 240
9.3.14 Cytograft Tissue Engineering 242
9.3.15 Flexible Stenting Solutions 244
9.3.16 IDEV Technologies 246
9.3.17 Kyoto Medical Planning 247
9.3.18 Medtronic 250
9.3.19 Nexeon Stent 252
9.3.20 Nipro Corporation 254
9.3.21 NovoStent Corporation 255
9.3.22 OptiMed 257
9.3.23 PeriTec Biosciences 259
9.3.24 Synergy Flow 260
9.3.25 Tepha 262
9.3.26 Terumo Corporation 264
9.3.27 TissueGen 266
9.3.28 Translumina 267
9.3.29 Vascular Concepts 269
9.3.30 Veryan Medical 270
9.3.31 VueKlar Cardiovascular 272
9.3.32 W.L. Gore & Associates 273
9.3.33 Zorion Medical 275
10 Market Drivers, Opportunities and Barriers 277
10.1 Market Drivers 277
10.1.1 Rising Prevalence of Disease 278
10.1.2 Long-Term Vessel Patency 279
10.1.3 Reducing the Risk of Restenosis 280
10.1.4 Low-Profile Stent System 280
10.1.5 Self-Expanding Nitinol Stents 282
10.1.6 Limb Amputation 282
10.1.7 Cost Considerations 283
10.1.8 Availability of Long-Term Data 283
10.1.9 Avoiding Stent-in-Stent Procedures 284
10.1.10 Reducing the Need for Dual Anti-Platelet Therapy 284
10.1.11 Accurate Stent Placement 285
10.1.12 Expected Launch of Vascular Stent Products in the US 285
10.2 Opportunities 286
10.2.1 Peripheral Stent Market 286
10.2.2 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 289
10.2.3 Biodegradable and Bioabsorbable Stents 290
10.2.4 Target High-Risk Patients 291
10.2.5 Launch Vascular Stents in the Japanese Market 291
10.2.6 Emerging Markets 292
10.3 Market Barriers 292
10.3.1 Slow Adoption 292
10.3.2 High Selling Prices 296
10.3.3 Lack of Reimbursement 296
10.3.4 Substitutes 297
11 US Market Outlook and Forecast 298
11.1 Overview 298
11.2 Market Analysis 298
11.2.1 Adoption of Drug-Eluting and Bioabsorbable Stents 300
12 Appendix 302
12.1 Bibliography 302
12.2 Abbreviations 321
12.3 Report Methodology 324
12.3.1 Overview 324
12.3.2 Coverage 324
12.3.3 Secondary Research 324
12.3.4 Forecasting Methodology 325
12.4 Physicians and Specialists Included in this Study 326
12.5 Physician Survey 328
12.6 About the Authors 329
12.6.1 Analysts 329
12.6.2 Global Head of Healthcare 330
12.7 About MediPoint 330
12.8 About GlobalData 330
12.9 Contact Us 331
12.10 Disclaimer 331

List of Tables

Table 1: Classification Systems for Determining the Severity of PAD Symptoms 30
Table 2: Risk Factors Associated with Peripheral Artery Disease 32
Table 3: Types of Atherosclerotic Lesions 33
Table 4: TASC II Classification of Iliac Artery Lesions 36
Table 5: TASC II Classification of Femoropopliteal Artery Lesions 37
Table 6: TASC II Classification of Infrapopliteal Artery Lesions 38
Table 7: Complications of Peripheral Artery Bypass Surgery 44
Table 8: Drugs Incorporated Into Drug-Eluting Stents 47
Table 9: Types of Lesions Treated Using Atherectomy 50
Table 10: Prevalence of PAD in Population Age ?65 Years in the US, millions, 2010-2019 58
Table 11: Direct and Indirect Healthcare Costs 59
Table 12: Healthcare Expenditures ($bn) for PAD in US. 2010-2019 60
Table 13: US Mean Hospital Costs* for Peripheral Revascularization Procedures, 2010–2019 ($US) 61
Table 14: Medicare National Average of Inpatient Hospital Payment for Peripheral and Coronary Stenting, 2012–2013 83
Table 15: US Peripheral Vascular Stent Market ($m) for Each Type of Artery in the Lower Extremity, 2012 91
Table 16: Marketed Bare Metal Stent Products 93
Table 17: Absolute Stent Family Product Portfolio 95
Table 18: Absolute Stent SWOT Analysis, 2013 98
Table 19: Astron Stent Product Portfolio 99
Table 20: Astron Stent SWOT Analysis, 2013 100
Table 21: BioMimics 3D Stent Product Portfolio 101
Table 22: BioMimics 3D Stent SWOT Analysis, 2013 102
Table 23: Complete Stent SE Product Portfolio 102
Table 24: Complete SE Stent SWOT Analysis, 2013 105
Table 25: E-Luminexx Stent Product Portfolio 106
Table 26: E-Luminexx Stent SWOT Analysis, 2013 107
Table 27: Epic Stent Product Portfolio 108
Table 28: Epic Stent SWOT Analysis, 2013 109
Table 29: FlexStent Iliac Stent System Product Portfolio 110
Table 30: FlexStent Iliac Stent System SWOT Analysis, 2013 111
Table 31: LifeStent Vascular Stent System Product Portfolio 112
Table 32: LifeStent Vascular Stent System SWOT Analysis, 2013 115
Table 33: Maris Deep Stent Product Portfolio 116
Table 34: Maris Deep Stent SWOT Analysis, 2013 117
Table 35: Maris Plus Stent Product Portfolio 118
Table 36: Maris Plus Stent SWOT Analysis, 2013 119
Table 37: Misago Stent Product Portfolio 120
Table 38: Misago Stent SWOT Analysis, 2013 122
Table 39: NovoStent Samba Stent System Product Portfolio 122
Table 40: NovoStent Samba Stent System SWOT Analysis, 2013 124
Table 41: Protégé Family of Stents Product Portfolio 125
Table 42: Protégé Family of Stents SWOT Analysis, 2013 127
Table 43: Pulsar 18 Stent Product Portfolio 128
Table 44: Pulsar 18 Stent SWOT Analysis, 2013 129
Table 45: SMART Stent Product Portfolio 130
Table 46: SMART Stent SWOT Analysis, 2013 132
Table 47: Sinus Stent Family Product Portfolio 133
Table 48: Sinus Stent Family SWOT Analysis, 2013 135
Table 49: Supera Veritas Stent Product Portfolio 136
Table 50: Supera Veritas Stent SWOT Analysis, 2013 138
Table 51: Wallstent Product Portfolio 139
Table 52: Wallstent SWOT Analysis, 2013 140
Table 53: Xpert Stent Product Portfolio 141
Table 54: Xpert Stent SWOT Analysis, 2013 143
Table 55: Zilver Stent Product Portfolio 144
Table 56: Zilver Stent SWOT Analysis, 2013 147
Table 57: Assurant Cobalt Stent Product Portfolio 148
Table 58: Assurant Cobalt Stent SWOT Analysis, 2013 149
Table 59: Chromis Deep Stent Product Portfolio 150
Table 60: Chromis Deep Stent SWOT Analysis, 2013 152
Table 61: Dynamic Stent Product Portfolio 153
Table 62: Dynamic Stent SWOT Analysis, 2013 153
Table 63: Express LD Product Portfolio 154
Table 64: Express LD SWOT Analysis, 2013 156
Table 65: IntraStent LD Stent Product Portfolio 157
Table 66: IntraStent LD Stent SWOT Analysis, 2013 157
Table 67: Omnilink Elite Stent Product Portfolio 158
Table 68: Omnilink Elite Stent SWOT Analysis, 2013 160
Table 69: ParaMount Mini GPS Product Portfolio 161
Table 70: ParaMount Mini GPS SWOT Analysis, 2013 161
Table 71: ProStar Stent Product Portfolio 162
Table 72: ProStar Stent SWOT Analysis, 2013 163
Table 73: Scuba Stent Product Portfolio 164
Table 74: Scuba Stent SWOT Analysis, 2013 165
Table 75: Visi-Pro Stent Product Portfolio 166
Table 76: Visi-Pro Stent SWOT Analysis, 2013 167
Table 77: Marketed Drug-Eluting Stent Products 167
Table 78: Xience Prime BTK Stent Product Portfolio 168
Table 79: Xience Prime BTK Stent SWOT Analysis, 2013 169
Table 80: Zilver PTX Stent Product Portfolio 170
Table 81: Zilver PTX Stent SWOT Analysis, 2013 173
Table 82: Marketed Covered Stent Products 173
Table 83: Gore Viabahn Stent Product Portfolio 174
Table 84: Gore Viabahn Stent SWOT Analysis, 2013 178
Table 85: Gore Tigris Stent Product Portfolio 179
Table 86: Gore Tigris Stent SWOT Analysis, 2013 180
Table 87: V12 Covered Stents Product Portfolio 180
Table 88: V12 Covered Stents SWOT Analysis, 2013 183
Table 89: Remedy Stent Product Portfolio 184
Table 90: Remedy Stent SWOT Analysis, 2012 185
Table 91: Global Peripheral Vascular Stent Product Pipeline 188
Table 92: Citation Stent SWOT Analysis, 2013 189
Table 93: MR-Enhanced Stents SWOT Analysis, 2013 190
Table 94: Yukon Stent SWOT Analysis, 2013 192
Table 95: iCAST Stent SWOT Analysis, 2013 194
Table 96: Peritoneal-Lined Stents SWOT Analysis, 2013 195
Table 97: Esprit BVS SWOT Analysis, 2013 197
Table 98: Magic Explorer Stent SWOT Analysis, 2013 198
Table 99: Stanza Stent SWOT Analysis, 2013 199
Table 100: 3D Biotek Bioresorbable Stent SWOT Analysis, 2013 200
Table 101: Archer Stent SWOT Analysis, 2013 201
Table 102: Abbott Vascular Company Profile 218
Table 103: Abbott Vascular, Marketed and Pipeline Vascular Stent Products 219
Table 104: Abbott Vascular SWOT Analysis, 2013 219
Table 105: Amaranth Medical Company Profile 220
Table 106: Amaranth Medical, Pipeline Vascular Stent Products 221
Table 107: Amaranth Medical SWOT Analysis, 2013 221
Table 108: Arterial Remodeling Technologies Company Profile 222
Table 109: Arterial Remodeling Technologies’ Pipeline Vascular Stent Products 223
Table 110: Arterial Remodeling Technologies SWOT Analysis, 2013 223
Table 111: Atrium Medical Corporation Company Profile 224
Table 112: Atrium Medical Corporation, Marketed and Pipeline Vascular Stent Products 225
Table 113: Atrium Medical Corporation SWOT Analysis, 2013 225
Table 114: Bard Peripheral Vascular (C.R. Bard) Company Profile 226
Table 115: Bard Peripheral Vascular (C.R. Bard), Marketed Stent Products 227
Table 116: Bard Peripheral Vascular (C.R. Bard) SWOT Analysis, 2013 227
Table 117: Biotronik Company Profile 228
Table 118: Marketed and Pipeline Vascular Stent Products by Biotronik 229
Table 119: Biotronik SWOT Analysis, 2013 229
Table 120: Boston Scientific Corporation Company Profile 230
Table 121: Boston Scientific Corporation, Marketed and Pipeline Vascular Stent Products 231
Table 122: Boston Scientific Corporation SWOT Analysis, 2013 231
Table 123: Company Profile – 3D Biotek 232
Table 124: 3D Biotek’s Pipeline Vascular Stent Products 233
Table 125: 3D Biotek SWOT Analysis, 2013 233
Table 126: 480 Biomedical Company Profile 233
Table 127: 480 Biomedical, Pipeline Vascular Stent Products 234
Table 128: 480 Biomedical SWOT Analysis, 2013 234
Table 129: Cook Medical Company Profile 235
Table 130: Cook Medical, Marketed Vascular Stent Products 236
Table 131: Cook Medical SWOT Analysis, 2013 236
Table 132: Cordis Corporation Company Profile 237
Table 133: Cordis Corporation’s Marketed Vascular Stent Products 238
Table 134: Cordis Corporation SWOT Analysis, 2013 238
Table 135: CorInnova Company Profile 239
Table 136: CorInnova, Pipeline Vascular Stent Products 239
Table 137: CorInnova SWOT Analysis, 2013 240
Table 138: Covidien Company Profile 240
Table 139: Covidien’s Marketed Vascular Stent Products 241
Table 140: Covidien SWOT Analysis, 2013 242
Table 141: Company Profile – Cytograft Tissue Engineering 242
Table 142: Cytograft Tissue Engineering, Pipeline Vascular Stent Products 243
Table 143: Cytograft Tissue Engineering SWOT Analysis, 2013 244
Table 144: Flexible Stenting Solutions Company Profile 244
Table 145: Flexible Stenting Solutions’ Marketed Vascular Stent Products 245
Table 146: Flexible Stenting Solutions SWOT Analysis, 2013 245
Table 147: IDEV Technologies Company Profile 246
Table 148: IDEV Technologies’ Marketed Vascular Stent Products 247
Table 149: IDEV Technologies SWOT Analysis, 2013 247
Table 150: Kyoto Medical Planning Company Profile 248
Table 151: Kyoto Medical Planning’s Marketed Vascular Stent Product 249
Table 152: Kyoto Medical Planning SWOT Analysis, 2013 249
Table 153: Medtronic Company Profile 250
Table 154: Medtronic’s Marketed and Pipeline Vascular Stent Products 251
Table 155: Medtronic SWOT Analysis, 2013 252
Table 156: Nexeon Stent Company Profile 252
Table 157: Nexeon Stent’s Pipeline Vascular Stent Product 253
Table 158: Nexeon Stent SWOT Analysis, 2013 253
Table 159: Nipro Corporation Company Profile 254
Table 160: Nipro Corporation’s Pipeline Vascular Stent Product 254
Table 161: Nipro Corporation SWOT Analysis, 2013 255
Table 162: NovoStent Corporation Company Profile 255
Table 163: NovoStent Corporation’s Marketed Vascular Stent Product 256
Table 164: NovoStent Corporation SWOT Analysis, 2013 256
Table 165: OptiMed Company Profile 257
Table 166: OptiMed’s Marketed Vascular Stent Products 258
Table 167: OptiMed SWOT Analysis, 2013 258
Table 168: Company Profile – PeriTec Biosciences 259
Table 169: PeriTec Bioscience’s Pipeline Vascular Stent Product 260
Table 170: PeriTec Biosciences SWOT Analysis, 2013 260
Table 171: Synergy Flow Company Profile 260
Table 172: Pipeline Vascular Stent Product by Synergy Flow 261
Table 173: Synergy Flow SWOT Analysis, 2013 261
Table 174: Tepha Company Profile 262
Table 175: Tepha Medical Device’s Pipeline Vascular Stent Product 263
Table 176: Tepha SWOT Analysis, 2013 263
Table 177: Terumo Corporation Company Profile 264
Table 178: Terumo Corporation’s Marketed Vascular Stent Products 265
Table 179: Terumo Corporation SWOT Analysis, 2013 265
Table 180: TissueGen Company Profile 266
Table 181: TissueGen’s Pipeline Vascular Stent Product 266
Table 182: TissueGen SWOT Analysis, 2013 267
Table 183: Translumina Company Profile 267
Table 184: Translumina’s Pipeline Vascular Stent Product 268
Table 185: Translumina SWOT Analysis, 2013 268
Table 186: Vascular Concepts Company Profile 269
Table 187: Marketed Vascular Stent Products by Vascular Concepts 269
Table 188: Vascular Concepts SWOT Analysis, 2013 270
Table 189: Company Profile – Veryan Medical 270
Table 190: Marketed Vascular Stent Products by Veryan Medical 271
Table 191: Veryan Medical SWOT Analysis, 2013 271
Table 192: VueKlar Cardiovascular Company Profile 272
Table 193: VueKlar Cardiovascular’s Pipeline Vascular Stent Product 272
Table 194: VueKlar Cardiovascular SWOT Analysis, 2013 273
Table 195: W.L. Gore & Associates Company Profile 273
Table 196: W.L. Gore & Associates’ Marketed Vascular Stent Products 274
Table 197: W.L. Gore & Associates SWOT Analysis, 2013 274
Table 198: Zorion Medical Company Profile 275
Table 199: Pipeline Vascular Stent Products by Zorion Medical 275
Table 200: Zorion Medical SWOT Analysis, 2013 276
Table 201: Peripheral Vascular Stent Sales ($m) Forecast for the United States, 2010–2019 298
Table 202: Physicians Surveyed, By Country 328

List of Figures

Figure 1: Peripheral Arteries of the Lower Extremity 27
Figure 2: Pathophysiology of Peripheral Artery Disease 29
Figure 3: Treatment Modalities – Peripheral Artery Disease 39
Figure 4: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only, US, 2012 (n=5) 40
Figure 5: Treatment of PAD, US, 2012 and 2018 (n=5) 43
Figure 6: Types of Stents Used to Treat Peripheral Artery Disease 46
Figure 7: Bare Metal Stent For Treating Peripheral Artery Disease 46
Figure 8: Drug-Eluting Stent for Treating Peripheral Artery Disease 47
Figure 9: Covered Stents For Treating Peripheral Artery Disease 48
Figure 10: Types of Atherectomy 51
Figure 11: Global Prevalence of PAD in Population Age ?65 Years in the Major Markets, millions, 2010–2019 58
Figure 12: Healthcare Expenditures ($bn) for PAD in US, 2010-2019 60
Figure 13: US Mean Hospital Costs* for Peripheral Revascularization Procedures, 2010–2019 62
Figure 14: Percent of PAD Patients With Restenosis After Stenting in the Peripheral Arteries in the Lower Extremity, US, 2012 (n=5) 70
Figure 15: Population (? 65 years) of PAD Patients Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, US, 2010–2019 76
Figure 16: Population (? 65 years) of PAD Patients Receiving Stenting for the Peripheral Arteries in the Lower Extremity, US, 2010–2019 77
Figure 17: Medicare National Average of Outpatient Hospitalization Payment for Endovascular Procedures in the Lower Extremity, 2011–2012 83
Figure 18: US Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity ($), 2012 90
Figure 19: US Peripheral Vascular Stent Market ($m) for Each Type of Artery, 2012 92
Figure 20: Remedy Stent for Treating Peripheral Artery Disease 184
Figure 21: Pipeline Peripheral Vascular Stent Products, 2013 186
Figure 22: Global Peripheral Vascular Stent Pipeline by Stage of Clinical Development, 2013 187
Figure 23: Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Company Share (%), 2012 214
Figure 24: Peripheral Vascular Stent Market for Each Type of Artery, Company Share (%), 2012 216
Figure 25: Kyoto Medical Planning, Sales Volume ($m), May 2002–May 2012 248
Figure 26: Likelihood of Physician Adoption of Each Type of Vascular Stent in the Future for Treating Peripheral Artery Disease in the Lower Extremity, Global (n=50) 287
Figure 27: Importance of Each Attribute in Adopting Vascular Stents to Treat Peripheral Artery Disease in the Lower Extremity, Global, (n=50) 288
Figure 28: US Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 299

Companies Mentioned

  • Abbott Vascular
  • Amaranth Medical
  • Arterial Remodeling Technologies
  • Atrium Medical Corporation
  • Bard Peripheral Vascular (C.R. Bard)
  • Biotronik
  • Boston Scientific Corporation
  • 3D Biotek
  • 480 Biomedical
  • Cook Medical
  • Cordis Corporation (Johnson & Johnson)

Read the full report:

MediPoint: Peripheral Vascular Stents for the Lower Extremity - US Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/medical_devices/medipoint_peripheral_vascular_stents_lower_extremity_us_analysis_market_forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reporbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com


Contact

  • Sarah Smith
    Research Advisor at Reportbuyer.com
    +44 208 816 85 48
    Email